Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended September 2024, Heron Therapeutics (HRTX) reported revenue of 0.03, compared to -36.4 million, representing a surprise of -9.86%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...